Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?

Published:2021-11-01 Issue:31 Volume:39 Page:3423-3426
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Ratain Mark J.¹²^ORCID,Tannock Ian F.²³^ORCID,Lichter Allen S.²^ORCID

Affiliation:

1. Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL

2. Optimal Cancer Care Alliance, Ann Arbor, MI

3. Division of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.21.01371

Reference30 articles.

1. Sotorasib for Lung Cancers with KRAS p.G12C Mutation

2. Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors

3. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

4. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial

5. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Camptothecin multifunctional nanoparticles effectively achieve a balance between the efficacy of breast cancer treatment and the preservation of intestinal homeostasis;Bioactive Materials;2024-11

2. MT-Keyboard: A Bayesian Model-Assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials;Statistics in Biopharmaceutical Research;2024-07-02

3. Sex as a Biological Variable in Early-Phase Oncology Clinical Trials: Enhancing the Path to Personalised Medicine;Heliyon;2024-06

4. Rethinking dose optimization in drug development;Cancer;2024-05-17

5. Design and sample size determination for multiple‐dose randomized phase II trials for dose optimization;Statistics in Medicine;2024-05-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3